Literature DB >> 22814980

Posterior reversible encephalopathy syndrome postautologous peripheral stem cell transplantation for multiple myeloma.

Shahriar Raj Zaman1.   

Abstract

This is a case of a 56-year-old lady with recent autologous peripheral stem cell transplantation for multiple myeloma. She was presented with a 48 h history of worsening headache, drowsiness, nausea/vomiting and some peripheral neurological symptoms. She developed status epilepticus, was intubated and transferred to intensive care unit. After full investigation with a CT head, CT cerebral angiogram, MRI brain and cerebral angiogram, she was diagnosed with posterior reversible encephalopathy syndrome (PRES) with the help of expert opinion, based on the clinical and radiological evidence. The MRI showed bilateral occipital signal changes suggestive of PRES. She was managed with nimodipine, phenytoin and clonazepam with good effect. Eventually extubated, she made good progress on the ward with no further seizure episodes. Functionally she did not appear to have any evidence of residual damage from the PRES. This case discusses PRES on a background of a haematological malignancy and its clinical features.

Entities:  

Mesh:

Year:  2012        PMID: 22814980      PMCID: PMC4543305          DOI: 10.1136/bcr-2012-006331

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Reversible posterior leukoencephalopathy syndrome: what have we learned in the last 10 years?

Authors:  Judith A Hinchey
Journal:  Arch Neurol       Date:  2008-02

Review 2.  Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review.

Authors:  V L Feigin; G J Rinkel; A Algra; M Vermeulen; J van Gijn
Journal:  Neurology       Date:  1998-04       Impact factor: 9.910

3.  Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: magnetic resonance imaging findings.

Authors:  R Bakshi; V E Bates; L L Mechtler; P R Kinkel; W R Kinkel
Journal:  Epilepsia       Date:  1998-03       Impact factor: 5.864

Review 4.  Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage.

Authors:  Alejandro A Rabinstein; Giuseppe Lanzino; Eelco Fm Wijdicks
Journal:  Lancet Neurol       Date:  2010-05       Impact factor: 44.182

5.  Pharmacological treatment of delayed cerebral ischemia and vasospasm in subarachnoid hemorrhage.

Authors:  Diego Castanares-Zapatero; Philippe Hantson
Journal:  Ann Intensive Care       Date:  2011-05-24       Impact factor: 6.925

Review 6.  Posterior reversible encephalopathy syndrome: a review.

Authors:  Steven K Feske
Journal:  Semin Neurol       Date:  2011-05-17       Impact factor: 3.420

7.  Posterior reversible encephalopathy syndrome: long-term follow-up.

Authors:  Christian Roth; Andreas Ferbert
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-12-01       Impact factor: 10.154

8.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

9.  Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage.

Authors:  G S Allen; H S Ahn; T J Preziosi; R Battye; S C Boone; S C Boone; S N Chou; D L Kelly; B K Weir; R A Crabbe; P J Lavik; S B Rosenbloom; F C Dorsey; C R Ingram; D E Mellits; L A Bertsch; D P Boisvert; M B Hundley; R K Johnson; J A Strom; C R Transou
Journal:  N Engl J Med       Date:  1983-03-17       Impact factor: 91.245

10.  Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies.

Authors:  C S Tam; J Galanos; J F Seymour; A G Pitman; R J Stark; H M Prince
Journal:  Am J Hematol       Date:  2004-09       Impact factor: 10.047

View more
  1 in total

Review 1.  Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review.

Authors:  Sheng Chen; Jun Hu; Liang Xu; Dixon Brandon; Jun Yu; Jianmin Zhang
Journal:  Mol Neurobiol       Date:  2015-12-14       Impact factor: 5.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.